Drug for Juvenile Arthritis Gets 'OK' from the FDA

The Food and Drug Administration has granted wider use of a drug for juvenile arthritis. Actemra was approved to treat children aged two years or older with active systemic juvenile idiopathic arthritis (SJIA), a rare illness for children.

Drug for Juvenile Arthritis Gets 'OK' from the FDA